Monheit Law Monheit Law - Personal Injury Attorneys
Monheit Health & Law News Articles

Monheit Law
Blog Home
By Month
Articles
Celebrex Lawsuits
Vioxx Lawsuits
Truck Accident Lawsuits
Serzone Lawsuits
Prempro Lawsuits
Welder's Disease Lawsuits
Ewing's Sarcoma Lawsuits
Risperdal Lawsuits
Crestor Lawsuits
Mesothelioma Lawsuits
Zprexa Lawsuits
Bextra Lawsuits


 Monheit Law : Blog Home : April 2007 : 2007-04-01

FDA announces marketing halt for GI drug, Zelnorm
April 1, 2007 06:39

Pharmaceutical News reports that the Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug. Novartis has agreed to voluntarily suspend marketing of the drug in the United States.

2006-07-18 «  » 2007-04-02
Philadelphia Lawyers - Pennsylvania Lawsuits at Monheit Law

Law Offices of Michael Monheit 1368 Barrowdale Road  Rydal, PA  19046
Call Us Toll Free: 866-761-1385  P: 215-840-6573  E: Michael@Monheit.com

AddThis Social Bookmark Button Home  |  Site Map  |  Blogs  |  Do I Have A Case?

© 2002-2010 - Monheit Law, P.C. - Philadelphia PA Personal Injury Law Firm. All rights reserved.
Location:  1368 Barrowdale Road, Jenkintown, PA 19046.  215-840-6573.

Personal Injury Attorney Disclaimer:  This website provides general information about Pennsylvania Personal Injury lawsuits and other legal information. Nothing on this site is intended to be legal advice. The materials on this site may be considered advertising. Nothing on this site constitutes the formation of an attorney client relationship. This website is not intended to solicit clients outside the State of New Jersey or the Commonwealth of Pennsylvania. In order to discuss representation, we must personally speak with you and enter into a signed, written agreement for representation. By utilizing this site, you agree to the foregoing.